4791-23-5

Basic information

• Product Name: N-(ANILINOCARBONYL)-2-CHLOROACETAMIDE
• Synonyms: 1-(2-chloroacetyl)-3-phenylurea;2-Chloro-N-(phenylcarbaMoyl)acetaMide
• CAS NO: 4791-23-5
• Molecular Formula: C₉H₉ClN₂O₂
• Molecular Weight: 212.63
• Mol File: 4791-23-5.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• Density: 1.36g/cm³
• Refractive Index: 1.602
• CAS DataBase Reference: N-(ANILINOCARBONYL)-2-CHLOROACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(ANILINOCARBONYL)-2-CHLOROACETAMIDE(4791-23-5)
• EPA Substance Registry System: N-(ANILINOCARBONYL)-2-CHLOROACETAMIDE(4791-23-5)

Safety Data

• Hazardous Substances Data: 4791-23-5(Hazardous Substances Data)

Usage

General Description

N-(Anilinocarbonyl)-2-chloroacetamide is a chemical compound with the molecular formula C9H8ClNO2. It is an organic compound containing an anilinocarbonyl group and a 2-chloroacetamide group. It is commonly used as a building block in organic synthesis and pharmaceutical research due to its ability to participate in various chemical reactions. N-(ANILINOCARBONYL)-2-CHLOROACETAMIDE has potential applications in the development of new drugs and as a precursor for the synthesis of other organic compounds. It is important to handle and use this compound with caution, as it may have hazardous properties and should be used in a controlled laboratory environment.

InChI:InChI=1/C9H9ClN2O2/c10-6-8(13)12-9(14)11-7-4-2-1-3-5-7/h1-5H,6H2,(H2,11,12,13,14)

Upstream product

• 62-53-3 aniline 
• 79-37-8 oxalyl dichloride 
• 79-07-2 Chloroacetamide 
• 4461-30-7 2-chloroacetylisocyanate 
• 142-04-1 aniline hydrochloride 
• 174968-74-2 6-chloromethyl 3-phenyl 2,4-dioxo 2,4-H 1,3,5-oxadiazine 
• 103-71-9 phenyl isocyanate 
• 64-10-8 phenyl carbamate 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 76979-52-7 1-{2-[(4-Oxo-4H-quinazolin-3-ylmethyl)-amino]-acetyl}-3-phenyl-urea 
• 1613583-39-3 2-((4-phenyl-6-(p-tolylamino)pyrimidin-2-yl)thio)-N-(phenylcarbamoyl)acetamide 
• 1629910-36-6 2-((4-((4-fluorophenyl)amino)-6-phenylpyrimidin-2-yl)thio)-N-(phenylcarbamoyl)acetamide 
• 1629910-37-7 2-((4-((4-chlorophenyl)amino)-6-phenylpyrimidin-2-yl)thio)-N-(phenylcarbamoyl)acetamide 
• 1613583-44-0 2-((4-chloro-6-phenylpyrimidin-2-yl)thio)-N-(phenylcarbamoyl)acetamide 
• 1613583-42-8 2-((4-hydroxy-6-phenylpyrimidin-2-yl)thio)-N-(phenylcarbamoyl)acetamide 

Relevant articles and documents

Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance

P-glycoprotein (ABCB1)-mediated multidrug resistance (MDR) has become a major obstacle in successful cancer chemotherapy, which attracted much effort to develop clinically useful compounds to reverse MDR. Here, we designed and synthesized a novel series o

Design, Synthesis, and Antitumor Activity Evaluation of Trifluoromethyl-Substituted Pyrimidine Derivatives Containing Urea Moiety

Abstract: In order to find efficient new antitumor drugs, a series of novel pyrimidine derivatives containing urea moiety were designed and synthesized, and the antitumor activity of four human tumor cells was evaluated by MTT analysis. The results showed that most of the target compounds exhibited moderate antitumor activity. In particular, the IC50 (concentration required to achieve 50% inhibition of the tumor cell proliferation) value of compound 2-((4-(4-ethylphenoxy)-6-(trifluoromethyl)pyrimidin-2-yl)thio)-N-((4-ethylphenyl)carba-moyl)acetamide for MGC-803 (human gastric carcinoma cell line) was 2.51 ± 0.17 μmol L–1, the anti-proliferative activity was significantly better than the positive control drug 5-fluorouracil. Molecular docking revealed that this compound can bind well to the active site of epidermal growth factor receptor (EGFR), and it may become a potential antitumor drug.

ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS

The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.